1903 completed, 312 terminated, 210 active not recruiting, 183 recruiting. 1086 Phase 2, 920 Phase 1, 430 Phase 3, 149 Phase 4, 93 Not applicable.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants. BMS-986446, Placebo - Healthy Volunteers | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 10 | 2027-02-10 | 2026-10-01 |
| A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia Xanomeline/trospium - Schizophrenia; Psychosis, Cognitive Impairment | Phase 3 | Not yet recruiting | European Group for Research In Schizophrenia | 171 | 2027-01-01 | 2026-05-13 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis BMS-986278 - Pulmonary Fibrosis | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2380 | 2026-12-16 | 2026-08-14 |
| A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 80 | 2026-11-30 | 2026-10-13 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Healthy Adult Participants BMS-986485, BMS-986485 matching placebo - Healthy Volunteers | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 50 | 2026-11-03 | 2026-10-21 |
| An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial Educational Intervention, Interview, Questionnaire Administration - Lung Carcinoma | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 60 | 2026-11-01 | 2026-10-16 |
| Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Repotrectinib - Non-Small Cell Lung Cancer | Not yet recruiting | Bristol-Myers Squibb | 10 | 2026-10-31 | 2026-09-30 | |
| A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder BMS-986511, Placebo - Major Depressive Disorder | Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 200 | 2026-10-30 | 2026-09-04 |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 56 | 2026-10-14 | 2026-07-17 |
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 176 | 2026-10-02 | 2026-09-28 |
| Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events Sarilumab, ICI Therapy - Any Advanced Solid Tumors | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 41 | 2026-10-01 | 2026-09-23 |
| Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas Golcadomide, Pemetrexed, Rituximab - Large B-cell Lymphoma, Central Nervous System Lymphoma | Phase 1 | Not yet recruiting | Allison Winter | 18 | 2026-10-01 | 2026-08-21 |
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-09-30 | 2026-09-11 |
| Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not yet recruiting | Bristol-Myers Squibb | 800 | 2026-09-30 | 2026-09-29 | |
| A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants Navlimetostat, [14C]Navlimetostat - Healthy Female Participants | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 6 | 2026-09-16 | 2026-08-20 |
| A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis BMS-986528 - Arthritis, Rheumatoid | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 84 | 2026-09-15 | 2026-09-22 |
Showing 20 of 2879. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (171) · Melanoma (170) · HIV Infections (145) · Neoplasms (118) · Arthritis, Rheumatoid (117) · Diabetes Mellitus, Type 2 (95) · Multiple Myeloma (89) · Hepatitis C (86) · Breast Neoplasms (68) · Neoplasm Metastasis (67) · Lung Neoplasms (66) · Colorectal Neoplasms (63) · Acquired Immunodeficiency Syndrome (61) · Carcinoma, Renal Cell (60) · Atrial Fibrillation (56)
Nivolumab (684) · Ipilimumab (331) · Abatacept (147) · Dasatinib (113) · Carboplatin (99) · Paclitaxel (92) · Cetuximab (86) · apixaban (76) · deucravacitinib (75) · Cisplatin (73) · Atazanavir Sulfate (62) · Dexamethasone (62) · daclatasvir (60) · relatlimab (51) · Didanosine (48)
United States (1982) · France (499) · Canada (486) · Germany (447) · Spain (447) · Italy (414) · United Kingdom (372) · Australia (367) · Poland (283) · Japan (262) · Belgium (259) · Argentina (250) · Netherlands (239) · Mexico (225) · South Korea (215)
Deborah Price, MSc (7) · Dung Le, MD (4) · Anil Gehi, MD (3) · David R. Spigel, MD (3) · Georgina Long (3)
PMID 38770818, PMID 26894924, PMID 25667295, PMID 35570249, PMID 39504507, PMID 25889498, PMID 28878934, PMID 20844485, PMID 24695685, PMID 26683763, PMID 27461213, PMID 29329602, PMID 30215677, PMID 36648215, PMID 25649350, PMID 26188837, PMID 27402391, PMID 29534336, PMID 32691060, PMID 33368935, PMID 33687069, PMID 35623069, PMID 36897427, PMID 39602111, PMID 40066907, PMID 40113724, PMID 40302153, PMID 42563042, PMID 16183552, PMID 17666313, PMID 18305915, PMID 18557952, PMID 19723613, PMID 20024643, PMID 20133267, PMID 21917607, PMID 21917625, PMID 22504093, PMID 23279103, PMID 24107588, PMID 24722180, PMID 24831918, PMID 24844912, PMID 27229685, PMID 28662232, PMID 29023213, PMID 29408986, PMID 29489427, PMID 30756462, PMID 31168885
2016 (43), 2018 (39), 2017 (38), 2015 (28), 2025 (26), 2014 (25), 2023 (25), 2019 (22), 2009 (19), 2008 (8), P30CA060553 (8), P30CA138292 (7), P30CA093373 (4), 2005 (3), P01CA247886 (3)